Mission
Support S.O.S.
Donate
Take Action
S.O.S. Drug Policy Newsletter & Legislative Updates
DEA Moves to Temporarily Schedule 7-Hydroxymitragynine (7-OH) and Related Substances
The U.S. Drug Enforcement Administration (DEA) has issued two Notices of Intent to temporarily place 7-hydroxymitragynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act (CSA). This temporary scheduling includes: 7-Hydroxymitragynine (7-OH), Mitragynine pseudoindoxyl (MP), Dihydro-7-hydroxymitragynine (MGM-15), and 9-fluoro derivative of 7-hydroxymitragynine (MGM-16). These substances exhibit psychoactive, opioid-like effects, have unpredictable potency, no currently accepted medical Continue Reading
Read more
Children Should Never Be the Cost of Marijuana Commercialization
A new study analyzing 25 years of poison control center data found pediatric marijuana exposures have increased dramatically since 2009. Researchers report more than a 6,000% increase among children under age six, raising important questions about cannabis commercialization, child safety, and the need for stronger public health protections.
Read more
The 2026 National Drug Control Strategy: Strengthening Prevention, Recovery, and Public Safety
The White House Office of National Drug Control Policy recently released the 2026 National Drug Control Strategy, emphasizing prevention, recovery, public safety, youth engagement, and addressing emerging drug threats including fentanyl, marijuana, and other psychoactive substances.
Read more
